🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)

    Universal Integrated

    Bowel Preparation

    phase 3 small molecule completed

    1 trial

  2. Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch

    Lacuna Pharma Pty Ltd

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial

  3. RAD001

    Novartis Pharmaceuticals

    Tuberous Sclerosis Complex-associated Refractory Seizures

    phase 3 small molecule completed

    1 trial

  4. RAPIBLOC 300 mg, poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  5. REGN7508

    Regeneron UK Limited

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  6. REGN7508

    Regeneron UK Limited

    Venous Thromboembolism (VTE)

    phase 3 small molecule active

    2 trials

  7. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Carcinoma, Squamous Cell of the Head and Neck

    phase 3 mab completed

    2 trials

  8. REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion, NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  9. RIFADINE 300 mg, gélule, ANSATIPINE 150 mg, gélule

    Tour Hekla

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    phase 3 small molecule active

    1 trial

  10. RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE

    Takeda

    Active Chronic Pouchitis

    phase 3 small molecule active

    1 trial

  11. RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D

    Hoffmann-La Roche

    Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068

    Hoffmann-La Roche

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  13. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  14. Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

    Sanofi-aventis Healthcare Pty Ltd

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  15. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Gout

    phase 3 small molecule active

    2 trials

  16. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  17. Recombinant SARS-CoV-2 fusion protein vaccine (V-01)

    Livzon Pharmaceutical Group

    COVID-19 Pandemic

    phase 3 mab active

    1 trial

  18. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  19. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  20. Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  21. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  22. Rilonacept

    Regeneron UK Limited

    Acute Gout Flare

    phase 3 small molecule completed

    1 trial

  23. Rilonacept

    Regeneron UK Limited

    Gout

    phase 3 mab completed

    3 trials

  24. Rilonacept 80 mg

    Regeneron UK Limited

    Intercritical Gout

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources